Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down-regulating ERK1/2-NF-κB and JAK/STAT signaling pathways

Journal of Neurochemistry

Volumn 133, Issue 1, 2015, Pages 104-112

  Zhang, Jian ^a   Zeng, Yu Qi ^a   Zhang, Jing ^a   Pan, Xiao Dong ^a   Kang, De Yong ^a   Huang, Tian Wen ^a   Chen, Xiao Chun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

cytokine; experimental autoimmune encepha lomyelitis; JAK STAT pathway; NF B pathway; transcription factor; tripchlorolide

Indexed keywords

AMINOTRANSFERASE; CREATININE; GAMMA INTERFERON; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RORRT; TRANSCRIPTION FACTOR T BET; TRIPCHLOROLIDE; UNCLASSIFIED DRUG; DITERPENE; PHENANTHRENE DERIVATIVE; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; ERYTHROCYTE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; LEUKOCYTE; LUMBAR SPINAL CORD; MOUSE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK REDUCTION; SCORING SYSTEM; SIGNAL TRANSDUCTION; THROMBOCYTE; ANIMAL; C57BL MOUSE; DEMYELINATING DISEASE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; PATHOLOGY; SPINAL CORD;

ANIMALIA; MUS; TRIPTERYGIUM WILFORDII;

ANIMALS; DEMYELINATING DISEASES; DITERPENES; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; JANUS KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; PHENANTHRENES; SIGNAL TRANSDUCTION; SPINAL CORD; STAT1 TRANSCRIPTION FACTOR;

EID: 84924589228     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13058     Document Type: Article

References (47)

1. Agrawal A., Dillon S., Denning T. L., and, Pulendran B., (2006) ERK1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 176, 5788-5796.
2. Berard J. L., Wolak K., Fournier S., and, David S., (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58, 434-445.
3. Bolton C., (2007) The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Inflammopharmacology 15, 183-187.
4. Bonetti B., Stegagno C., Cannella B., Rizzuto N., Moretto G., and, Raine C. S., (1999) Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am. J. Pathol. 155, 1433-1438.
5. Cohen J. A., (2009) Corticosteroids in combination therapy for multiple sclerosis. Lancet Neurol. 8, 502-503.
6. Dello Russo C., Lisi L., Feinstein D. L., and, Navarra P., (2013) mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia 61, 301-311.
7. Denic A., Johnson A. J., Bieber A. J., Warrington A. E., Rodriguez M., and, Pirko I., (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18, 21-29.
8. Dong C., (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8, 337-348.
9. El-behi M., Rostami A., and, Ciric B., (2010) Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 5, 189-197.
10. Fletcher J. M., Lalor S. J., Sweeney C. M., Tubridy N., and, Mills K. H., (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162, 1-11.
11. Frisullo G., Nociti V., Iorio R., Patanella A. K., Marti A., Mirabella M., Tonali P. A., and, Batocchi A. P., (2008) The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. J. Neuroimmunol. 205, 126-134.
12. Gold R., Linington C., and, Lassmann H., (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971.
13. Goodin D. S., Frohman E. M., Garmany G. P., Jr, Halper J., Likosky W. H., Lublin F. D., Silberberg D. H., Stuart W. H., and, van den Noort S., (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178.
14. Goverman J., (2009) Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9, 393-407.
15. Goverman J., Perchellet A., and, Huseby E. S., (2005) The role of CD8(+) T cells in multiple sclerosis and its animal models. Curr. Drug Targets Inflamm. Allergy 4, 239-245.
16. Han S., Zhang F., Hu Z., Sun Y., Yang J., Davies H., Yew D. T., and, Fang M., (2013) Dose-dependent anti-inflammatory and neuroprotective effects of an alphanubeta3 integrin-binding peptide. Mediators Inflamm. 2013, 268486.
17. Hilliard B., Samoilova E. B., Liu T. S., Rostami A., and, Chen Y., (1999) Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J. Immunol. 163, 2937-2943.
18. Jadidi-Niaragh F., and, Mirshafiey A., (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 74, 1-13.
19. Jones J. L., Anderson J. M., Phuah C. L., et al,. (2010) Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133, 2232-2247.
20. Lassmann H., (2007) Experimental models of multiple sclerosis. Rev. Neurol. (Paris) 163, 651-655.
21. Lassmann H., (2008) Models of multiple sclerosis: new insights into pathophysiology and repair. Curr. Opin. Neurol. 21, 242-247.
22. Liblau R., Steinman L., and, Brocke S., (1997) Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int. Immunol. 9, 799-803.
23. Lin N., Pan X. D., Chen A. Q., Zhu Y. G., Wu M., Zhang J., and, Chen X. C., (2014) Tripchlorolide improves age-associated cognitive deficits by reversing hippocampal synaptic plasticity impairment and NMDA receptor dysfunction in SAMP8 mice. Behav. Brain Res. 258, 8-18.
24. Liu X., Lee Y. S., Yu C. R., and, Egwuagu C. E., (2008) Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J. Immunol. 180, 6070-6076.
25. Lock C., Hermans G., Pedotti R., et al,. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508.
26. Mc Guire C., Prinz M., Beyaert R., and, van Loo G., (2013) Nuclear factor kappa B (NF-kappaB) in multiple sclerosis pathology. Trends Mol. Med. 19, 604-613.
27. McGeachy M. J., and, Anderton S. M., (2005) Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 32, 81-84.
28. Mitchell T. J., and, John S., (2005) Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114, 301-312.
29. Mycko M. P., Papoian R., Boschert U., Raine C. S., and, Selmaj K. W., (2003) cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 126, 1048-1057.
30. Oksenberg J. R., and, Baranzini S. E., (2010) Multiple sclerosis genetics-is the glass half full, or half empty? Nat. Rev. 6, 429-437.
31. Orton S. M., Wald L., Confavreux C., Vukusic S., Krohn J. P., Ramagopalan S. V., Herrera B. M., Sadovnick A. D., and, Ebers G. C., (2011) Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 76, 425-431.
32. O'Shea J. J., and, Plenge R., (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36, 542-550.
33. Pahan K., and, Schmid M., (2000) Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 287, 17-20.
34. Pan X. D., and, Chen X. C., (2008) Advances in the study of immunopharmacological effects and mechanisms of extracts of Tripterygium wilfordii Hook. f. in neuroimmunologic disorders. Yao Xue Xue Bao 43, 1179-1185.
35. Pan X. D., Chen X. C., Zhu Y. G., Zhang J., Huang T. W., Chen L. M., Ye Q. Y., and, Huang H. P., (2008) Neuroprotective role of tripchlorolide on inflammatory neurotoxicity induced by lipopolysaccharide-activated microglia. Biochem. Pharmacol. 76, 362-372.
36. Pan X. D., Chen X. C., Zhu Y. G., Chen L. M., Zhang J., Huang T. W., Ye Q. Y., and, Huang H. P., (2009) Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 57, 1227-1238.
37. Ramagopalan S. V., Handel A. E., Giovannoni G., Rutherford Siegel S., Ebers G. C., and, Chaplin G., (2011) Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 76, 1410-1414.
38. Ransohoff R. M., (2012) Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 15, 1074-1077.
39. Sawcer S., Hellenthal G., Pirinen M., et al,. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219.
40. Seavey M. M., and, Dobrzanski P., (2012) The many faces of Janus kinase. Biochem. Pharmacol. 83, 1136-1145.
41. Stromnes I. M., and, Goverman J. M., (2006) Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1, 1810-1819.
42. Tao X. L., (1989) Mechanism of treating rheumatoid arthritis with Tripterygium wilfordii hook. II. Effect on PGE2 secretion. Zhongguo yi xue ke xue yuan xue bao 11, 36-40.
43. Tao X., Cush J. J., Garret M., and, Lipsky P. E., (2001) A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J. Rheumatol. 28, 2160-2167.
44. Weaver C. T., Hatton R. D., Mangan P. R., and, Harrington L. E., (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852.
45. Yu D. Q., Zhang D. M., Wang H. B., and, Liang X. T., (1992) Structure modification of triptolide, a diterpenoid from Tripterygium wilfordii. Yao Xue Xue Bao 27, 830-836.
46. Zhang R., Tian A., Zhang H., Zhou Z., Yu H., and, Chen L., (2011) Amelioration of experimental autoimmune encephalomyelitis by beta-elemene treatment is associated with Th17 and Treg cell balance. J. Mol. Neurosci. 44, 31-40.
47. Zhang F., Yang J., Jiang H., and, Han S., (2014) An alphanubeta3 integrin-binding peptide ameliorates symptoms of chronic progressive experimental autoimmune encephalomyelitis by alleviating neuroinflammatory responses in mice. J. Neuroimmune Pharmacol. 9, 399-412.